Security Reports > Asterias Biotherapeutics

Asterias Biotherapeutics
Data Breaches, Cyber Attacks and Security Report

https://asteriasbiotherapeutics.com  ᛫ 
Last updated August 3, 2020

Asterias Biotherapeutics Security Rating

${grade.letter}
${cstarScore}
/ 950

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Asterias Biotherapeutics is implementing good security practices.

Company Information

Company:
${companyName}
Valuation:
${marketCap}
Employees:
${employees}
Location:
${country}
CEO:
${ceo}

About Asterias Biotherapeutics

BioTime, Inc. is a clinical-stage biotechnology company headquartered in Alameda, California. BioTime stock is traded on the New York Stock Exchange American Exchange under ticker symbol BTX. BioTime focuses primarily on aesthetics, ophthalmology and cell and drug delivery. The company is in clinical trials for dry age-related macular degeneration (dry AMD) and facial lipoatrophy in HIV patients.


Data Breaches and Security News


Security Report for Asterias Biotherapeutics

Want a security rating for your organization?

This report shows a preliminary security rating for Asterias Biotherapeutics. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.

Get a deeper scan

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Asterias Biotherapeutics's security performance with other companies